GGrantIndex
Sort

48,018 grants matching immunotherapy

Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens

$720,716
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Building better T cell receptors for targeted immunotherapy

$720,706
Brian M Baker · University Of Notre Dame · R01 · FY2018 · AI

Data-driven inference of regulators for cytokine-mediated tumor killing

$720,674
Peng Jiang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Computational approaches for the analyses of spatial profiling technologies

$720,674
Peng Jiang · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

CD4 T cell control of cytomegalovirus

$720,659
Christopher A Benedict · La Jolla Institute For Immunology · R01 · FY2019 · AI

CD4 T cell control of cytomegalovirus

$720,659
Christopher A Benedict · La Jolla Institute For Immunology · R01 · FY2020 · AI

Development of Broadly Protective Vaccines against New World Arenaviruses

$720,588
Yuying Liang · University Of Minnesota · R01 · FY2025 · AI

Depleting exosomes to improve responses to immune therapy in HNSCC

$720,532
Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · DE

Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy

$720,416
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

Mechanism of action and therapeutic utility of stimulatory CpG oligonucleotides

$720,328
Dennis Klinman · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

Systems-level identification of key regulators deciding immune cell state

$720,299
Wei Wang · University Of California, San Diego · R01 · FY2022 · AI

Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy

$720,185
Georg Michael Lauer · Massachusetts General Hospital · U19 · FY2019 · AI

Understanding and manipulating programmed cell death (PCD) pathways to facilitate lymphoid tumor killing by CAR T cells

$720,152
Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2021 · CA

TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors

$720,023
Craig M. Brackett · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA

Systems genetics analysis of tumor evolution in the mouse

$720,018
Allan Balmain · University Of California, San Francisco · R35 · FY2017 · CA

IMMUNOTHERAPY TARGETING STROMAL CD5L IN OVARIAN CANCER

$720,001
The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2020 · Defense Health Agency

Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma

$719,958
Tzu-Yin Lin · Theranostec, Inc. · R44 · FY2024 · CA

A Pathway for Necrotic Cell Death

$719,845
David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2025 · CA

Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor

$719,820
Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Probing cytosolic nucleic acid sensing pathways in cancer

$719,771
Ashley Marie Laughney · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA

Regulation of Expression and Mechanism of Action of Granulysin and RANTES

$719,644
Alan Krensky · Basic Sciences · Z01 · FY2007 · CA

ISLET TOLERANCE INDUCTION BASED ON ANTI-CD154 ANTIBODY

$719,594
Univ Of Massachusetts Med Sch Worcester · R01 · FY2000 · DK

Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma

$719,558
Xiuli Wang · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA

Preclinical development of breakthrough immunotherapy for brain tumors

$719,525
Hideho Okada · University Of California, San Francisco · R35 · FY2019 · NS

Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors

$719,445
Christopher C. Derenzo · St. Jude Children'S Research Hospital · R01 · FY2023 · CA